Pinaverium and Herbs for Irritable Bowel Syndrome Treatment: an Onset and Offset Study (PHIBEST)
A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome
1 other identifier
interventional
800
1 country
4
Brief Summary
The purpose of this study is to test the onset of action, offset of action, efficacy, and safety of pinaverium and an herbal medication for irritable bowel syndrome (IBS) for a long term (over one year). Pinaverium has been in many countries, but there is no randomized, double-blind, large sample size, and placebo-controlled study on this medication yet. Tong Xie Yao Fang (Formula for pain and diarrhea) is a historically and contemporarily used traditional Chinese medicine that can be used for IBS. The hypothesis is that the two remedies are effective and safe for IBS treatment with no significant different onset and offset of actions when tested by modern clinical standards and criteria.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 2012
Longer than P75 for not_applicable
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2014
CompletedFirst Submitted
Initial submission to the registry
December 29, 2014
CompletedFirst Posted
Study publicly available on registry
January 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2017
CompletedNovember 22, 2016
November 1, 2016
2.3 years
December 29, 2014
November 18, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Abdominal pain
0 = no pain, 10 worst pain
2 years
Primary endpoint --- vi) Form (appearance) of stool
Use Bristol stool scale.
2 years
Secondary Outcomes (4)
Frequency of the pain
2 year
# of stools per day
2 years
Abdominal discomfort
2 years
Frequency of discomfort
2 years
Other Outcomes (2)
IBS global symptom relief
2 years
Treatment-emergent adverse effect (TEAE) profiles.
2 years
Study Arms (3)
TCM (Traditional Chinese medicine)
ACTIVE COMPARATORFormula for pain and diarrhea, Atractylodes (\~10-15g), Paeonia Lactiflora (\~15-30g), Tangerine Peel (\~10g), Ledebouriella Root (\~10g), Radix codonopsitis (\~10-15g), Radix curcumae (\~10g), Fingered citron (\~10g), Tuckahoe (\~15g), etc.
Pinaverium
ACTIVE COMPARATORPlacebo
PLACEBO COMPARATORPlacebo is blindly given to patients
Interventions
To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
Atractylodes (\~10-15g)
Paeonia Lactiflora (\~15-30g)
Tangerine Peel (\~10g)
Ledebouriella Root (\~10g)
Radix codonopsitis (\~10-15g)
Radix curcumae (\~10g)
Fingered citron (\~10g)
Tuckahoe (15g)
Eligibility Criteria
You may qualify if:
- to 70 years old age group, male and female
- In accordance with the above Western medicine Rome III standards.
- In accordance with the above description of Deficient Spleen Qi and Liver Qi Stagnation
- Informed consent for treatment
- No change in appetite during treatments periods
You may not qualify if:
- Pregnant or lactation female patients, and Fertility male patients
- Present digestive system disease within current three months
- Take IBS medicines within ten days prior to treatment or during treatment
- Take depression medicine within ten days prior to treatment or during treatment
- Take pain reliever medicine within ten days prior to treatment or during treatment
- Have serious primary heart, liver, kidney, lung and blood system diseases, asthma, and Lung and liver dysfunction patients
- If an emergency occurs; a physician terminates the treatment
- Cannot comply with the rules and cannot cooperate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Second Jiangsu Provincial Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Traditional Chinese Medicine
Nanjing, Jiangsu, 210017, China
Jiangsu Provincial Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Traditional Chinese Medicine
Nanjing, Jiangsu, 210029, China
Beijing Xuanwu Hospital of Traditional Chinese Medicine affiliated to Capital Medical University.
Beijing, 100050, China
Shanghai First People's Hospital affiliated to Shanghai Tiao Tong University
Shanghai, 200240, China
Related Publications (1)
Zheng L, Lu W, Xiao Q, Lai Y, Fan H, Sun Y, Huang D, Wang Y, Li Z, Jiang Z, Liu X, Zhang L, Zuo D, Shou Z, Tang Q, Huang H, Yang Y, Tang Z, Xiao J. Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial. Sci Rep. 2021 Jul 6;11(1):13894. doi: 10.1038/s41598-021-92990-7.
PMID: 34230526DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Baiwen Li, MD
Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiao Tong University, 100 Haining Rd. Hongkou, Shanghai 200280, China.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 29, 2014
First Posted
January 1, 2015
Study Start
August 1, 2012
Primary Completion
November 1, 2014
Study Completion
May 1, 2017
Last Updated
November 22, 2016
Record last verified: 2016-11